Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.
Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback